[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,174,846
  • Shares Outstanding, K 56,436
  • Annual Sales, $ 738,260 K
  • Annual Income, $ 48,890 K
  • EBIT $ 65 M
  • EBITDA $ 160 M
  • 60-Month Beta 1.03
  • Price/Sales 13.48
  • Price/Cash Flow 51.62
  • Price/Book 4.71

Options Overview Details

View History
  • Implied Volatility 42.58% (+2.08%)
  • Historical Volatility 48.52%
  • IV Percentile 18%
  • IV Rank 15.31%
  • IV High 69.51% on 07/21/26
  • IV Low 37.71% on 12/19/25
  • Expected Move (DTE 28) 12.33 (6.80%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 77
  • Volume Avg (30-Day) 370
  • Put/Call OI Ratio 2.60
  • Today's Open Interest 11,690
  • Open Int (30-Day) 10,210
  • Expected Range 168.81 to 193.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.46
  • Number of Estimates 4
  • High Estimate $0.46
  • Low Estimate $0.45
  • Prior Year $0.46
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.03 +39.30%
on 07/27/26
188.73 -4.03%
on 08/20/26
+44.14 (+32.22%)
since 07/21/26
3-Month
112.00 +61.72%
on 05/27/26
188.73 -4.03%
on 08/20/26
+67.76 (+59.77%)
since 05/21/26
52-Week
100.99 +79.35%
on 05/14/26
188.73 -4.03%
on 08/20/26
+61.48 (+51.38%)
since 08/21/25

Most Recent Stories

More News
3 Hyped Up Stocks We Keep Off Our Radar

3 Hyped Up Stocks We Keep Off Our Radar

SWK : 100.02 (+1.18%)
NBTB : 52.09 (+0.40%)
RGEN : 181.13 (+0.47%)
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

RGEN : 181.13 (+0.47%)
2 Growth Stocks to Add to Your Roster and 1 We Avoid

2 Growth Stocks to Add to Your Roster and 1 We Avoid

SEZL : 119.11 (+1.44%)
RGEN : 181.13 (+0.47%)
HCI : 182.52 (+0.49%)
Why Repligen (RGEN) Stock Is Up Today

Why Repligen (RGEN) Stock Is Up Today

RGEN : 181.13 (+0.47%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

RGEN : 181.13 (+0.47%)
Repligen: Q2 Earnings Snapshot

Repligen: Q2 Earnings Snapshot

RGEN : 181.13 (+0.47%)
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% ...

RGEN : 181.13 (+0.47%)
Repligen (RGEN) Q2 Earnings: What To Expect

Repligen (RGEN) Q2 Earnings: What To Expect

RGEN : 181.13 (+0.47%)
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of BioLife Solutions ...

BLFS : 37.10 (+0.35%)
RGEN : 181.13 (+0.47%)
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

TXG : 65.12 (+1.96%)
HIMS : 33.78 (+6.03%)
RGEN : 181.13 (+0.47%)
WST : 353.08 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 190.47
2nd Resistance Point 186.45
1st Resistance Point 183.79
Last Price 181.13
1st Support Level 177.11
2nd Support Level 173.09
3rd Support Level 170.43

See More

52-Week High 188.73
Last Price 181.13
Fibonacci 61.8% 155.21
Fibonacci 50% 144.86
Fibonacci 38.2% 134.51
52-Week Low 100.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.